Announced
Financials
Tags
biopharmaceuticals
Minority
Acquisition
Public
Pending
Private Equity
Single Bidder
Pharmaceuticals
Friendly
Hong Kong
Synopsis
General Atlantic agreed to invest $100m in Chi-Med, an innovative biopharmaceutical company. The proceeds will fund ongoing research and clinical development and support the further growth of its commercialization capabilities both in China and globally. “Over the last few months, we have made significant development, regulatory and commercial progress in several oncology programs intended for the global market. We are delighted therefore to welcome General Atlantic to our existing shareholder base and to further strengthen our balance sheet. We are confident that in this phase of material progress for Chi-Med we can deliver innovative cancer therapies to patients internationally,” Christian Hogg, Chi-Med CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.